VEDBAEK, Denmark, June 21, 2010 (GLOBE NEWSWIRE) -- Exiqon A/S (Copenhagen:EXQ), today announced that it has granted a non-exclusive license to BD (Becton, Dickinson and Company) to use Exiqon’s proprietary locked nucleic acids (LNA(TM)) technology in defined products for infectious disease diagnostics.
